Mindray Medical International (NYSE: MR ) reported earnings on Nov. 5. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Mindray Medical International missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share contracted.
Gross margins expanded, operating margins dropped, net margins dropped.
Mindray Medical International logged revenue of $257.1 million. The six analysts polled by S&P Capital IQ hoped for sales of $266.1 million on the same basis. GAAP reported sales were 18% higher than the prior-year quarter's $218.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.42. The five earnings estimates compiled by S&P Capital IQ predicted $0.45 per share. GAAP EPS of $0.30 for Q3 were 3.2% lower than the prior-year quarter's $0.31 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 56.0%, 110 basis points better than the prior-year quarter. Operating margin was 15.2%, 250 basis points worse than the prior-year quarter. Net margin was 13.9%, 320 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $310.4 million. On the bottom line, the average EPS estimate is $0.54.
Next year's average estimate for revenue is $1.06 billion. The average EPS estimate is $1.81.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,353 members out of 1,388 rating the stock outperform, and 35 members rating it underperform. Among 282 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 268 give Mindray Medical International a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International is outperform, with an average price target of $35.51.